Expert: Blaming Greenpeace for blocking Golden Rice is “sleazy sleight of hand”
By Claire Robinson and Jonathan Matthews,
GMWatch
| 06. 02. 2024
With the recent Philippines court decision blocking the further planting of GM Golden Rice in the country, pro-GMO advocates have renewed their attacks on Greenpeace, which, with the farmer-scientist network MASIPAG and others, brought the lawsuit.
The Observer’s science editor Robin McKie has published an article accusing Greenpeace of causing “a catastrophe” by its role in the court case. GM Golden Rice is engineered to contain the vitamin A precursor beta-carotene and is targeted at poor people, especially children, suffering from vitamin A deficiency (VAD).
The Observer also chimed in with an editorial headlined, “When modified rice could save thousands of lives, it is wrong to oppose it”, and subtitled, “The green movement’s attempts to block the cultivation of a grain enhanced with vitamin A is misguided”.
However, experts on Golden Rice have roundly debunked the claims, with one pointing out that blaming Greenpeace for blocking the GM crop is “a sleazy sleight of hand to hide the fact that after 30 years of development, Golden Rice is still not ready”. Glenn Davis Stone, Research Professor of Environmental Science at Sweet...
Related Articles
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...